Please login to the form below

Not currently logged in
Email:
Password:

ALK-Abello appoints Søren Jelert as CFO

He will be based at the company’s headquarters in Denmark

Soren JelertDansih allergy immunotherapy company ALK-Abello has appointed Søren Jelert as its new chief financial officer, a role that sees him succeed Flemming Pederson at the pharmaceutical company.

Jelert most recently served as a general manager for NNE, an engineering company that specialises in supporting pharmaceutical company engineering projects.

He said: “This new role offers me the opportunity to use my knowledge and experience to support and further develop ALK as it works to build a new growth platform and to become a truly global allergy company.”

His career has seen him serve in various capacities for Novo Nordisk, including as finance director Europe North and manager operations, finance.

Carsten Hellmann, president and chief executive officer, ALK, said: “Søren brings a wealth of experience to ALK, in particular from his previous pharmaceutical industry-focused roles at NNE and Novo Nordisk.

“He has a proven track record of financial leadership and he has also played a pivotal role in transformation processes that are comparable to the one we are embarking upon at ALK.”

Jelert will be based at ALK’s headquarters in Hørsholm, Denmark and will report directly to Hellmann.

11th December 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics